Abstract
Leptomeningeal disease in metastatic non-small cell lung cancer remains a challenging condition with guarded prognosis. Although several EGFR TKI (in particular osimertinib) have been reported to have good intra-cranial activity, however this has not been reported for dacomitinib as yet. Of note, brain metastases patients were excluded from the dacomitinib registration trial ARCHER 1050. This is in spite of the fact that pre-clinical data shows good levels of dacomitinib in the brain in mice-models.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
